Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220 million Series C financing round led by Legend Capital. Other investors include Highlight Capital, C&D Emerging Industry Investment, New Alliance Capital, Service Trade Innovation Development Guidance Fund, Huatai Zijin Investment, Gf Xinde Investment, and Ciit Asset Management, alongside existing investor Hillhouse Investment. Notably, GenScript Biotech Corporation, its Chinese parent company, contributed $30 million to the round. The proceeds will be used to expand GenScript ProBio’s biologics and gene and cell therapy CDMO business, upgrade its technology platforms, and enhance synergies within the healthcare investment field.
Global CMC and CMO Projects
GenScript ProBio has undertaken over 80 global Chemistry, Manufacturing, and Controls (CMC) and Contract Manufacturing Organization (CMO) projects, including more than 20 Investigational New Drug (IND) applications worldwide. This financing round underscores the company’s commitment to advancing its global footprint and enhancing its capabilities in biologics and gene therapy manufacturing.
Future Outlook
With the support of this Series C funding, GenScript ProBio is well-positioned to accelerate its growth in the biologics and gene therapy sectors. The company’s focus on expanding its CDMO business and upgrading its technology platforms aligns with the growing demand for advanced manufacturing solutions in the life sciences industry.-Fineline Info & Tech
